RecruitingPhase 2Phase 3NCT07532603
A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Lichen Planopilaris
Sponsor
Priovant Therapeutics, Inc.
Enrollment
342 participants
Start Date
Mar 19, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Age ≥ 18 years
- Scalp biopsy consistent with LPP
- Active and symptomatic LPP at screening and baseline-
- Weight > 40 kg to < 130 kg with BMI ≤ 45 kg/m2
Exclusion Criteria4
- History of: Lymphoproliferative disorder; Active malignancy; History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid cancer).
- High risk of thrombosis or cardiovascular disease
- High risk of herpes zoster
- Active or recent infection
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGOral Brepocitinib
Oral
DRUGPlacebo
Oral
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07532603